SMALL CELL LUNG CANCER . SCIENCE DIRECT PUBLICÓ AYER META-ANALISIS CONCLUYENTE : TARLATAMAB Y NIVOLUMAB MEJORARON LA SUPERVIVENCIA GLOBAL ( OVERALL SURVIVAL / OS ) EN COMPARACIÓN CON OTROS TRATAMIENTOS , SIENDO TARLATAMAB EL QUE OBTUVO LA MEJOR PUNTUACIÓN ( SUCRA 0,96 ) ... """ Y ADEMÁS DEMOSTRÓ UNA SEGURIDAD SUPERIOR """.

 

TARLATAMAB ( IMDELLTRA BY AMGEN ) PARA EL TRATAMIENTO DE SEGUNDA LINEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE TIENE APROBACIÓN ACELERADA EN ESTADOS UNIDOS , CANADA , COREA Y REINO UNIDO ... LA AGENCIA EUROPEA DEL MEDICAMENTO ( EMA ) ESTÁ EN ELLO . 

CONCLUSIÓN :

TARLATAMAB PROPORCIONA LOS RESULTADOS MÁS FAVORABLES , LO QUE JUSTIFICA SU CONSIDERACIÓN COMO TERAPIA PREFERIDA  ( ESTÁNDAR ) PARA EL TRATAMIENTO DEL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS (.SCLC )  R/R PLATINO .

Systematic Review And Network Meta-Analysis: Evaluation Of Systemic Therapies For Platinum Refractory Or resistant SMALL CELL LUNG CANCER .

SCIENCE DIRECT . 3 NOVEMBER 2025 .

BACKGROUND :

Platinum-refractory/resistant (r/r) SMALL CELL LUNG CANCER ( SCLC ) is associated with poor prognosis and limited treatment options . While chemotherapy has been the standard, recent randomized controlled trials (RCTs) have investigated immunotherapy and targeted therapies. 

In 2025, the DeLLphi-304 trial showed TARLATAMAB significantly improved overall survival (OS) and progression-free survival (PFS) versus standard chemotherapy (SC). However, no network meta-analysis (NMA) has compared systemic therapies in this setting .

METHODS :

We systematically searched major Databases through June 2025 for PHASE III RCTs evaluating systemic therapies in platinum r/r SCLC .

 Extracted outcomes included OS, PFS, quality-of-life (QoL), overall response rate (ORR), and treatment-related adverse events (AEs) . Indirect comparisons were performed using Markov Chain Monte Carlo methods, with treatment rankings assessed via SUCRA probabilities .

RESULTS :

Six phase III RCTs were identified . TARLATAMAB and NIVOLUMAB improved OS over other treatments, with tarlatamab ranking highest (SUCRA 0.96) and demonstrating superior safety .

CONCLUSIONS :

TARLATAMAB provides the most favorable outcomes, supporting its consideration as a preferred therapy for platinum r/r SCLC .